To conserve cash to fund its COMP360 program, Compass also announced a corporate restructuring involving the downsizing of staff by ~30% as well as halting all its non-COMP360 pre- clinical studies
What is covered in the Full Insight:
Summary of Compass Pathways' Timeline Delays
Sector Impact of Compass's Announcement
Cybin's Unique Position and Risk Mitigation
Upcoming Catalysts for Cybin
Challenges in Psychedelic Drug Development
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.